PCMC
VYGR icon

Planning Capital Management Corporation’s Voyager Therapeutics VYGR Stock Holding History

Planning Capital Management Corporation’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$88 Hold
15
– – ﹤0.01% 723
2024
Q2 		$119 Buy
+15
New +$126 ﹤0.01% 662

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Planning Capital Management Corporation's VYGR Position: Q3 2024 in Review

Planning Capital Management Corporation held its Voyager Therapeutics (VYGR) position steady in Q3 2024 at 15 shares worth $88. The position accounts for ﹤0.01% of the portfolio, ranked #723.

Planning Capital Management Corporation first reported a position in VYGR in Q2 2024 and has held it in 2 quarters since. The position peaked at $119 in Q2 2024. 128 funds tracked by Wall St. Rank hold VYGR as of Q3 2024.

  • Planning Capital Management Corporation held 15 shares of Voyager Therapeutics worth $88 as of Q3 2024.
  • Planning Capital Management Corporation left its Voyager Therapeutics share count unchanged in Q3 2024.
  • Voyager Therapeutics made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #723 holding.
  • Planning Capital Management Corporation first reported a position in Voyager Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • Planning Capital Management Corporation's Voyager Therapeutics position peaked at $119 in Q2 2024.
  • 128 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.